ImmunityBio (IBRX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jun, 2026Opening remarks and agenda
The meeting was held virtually for the seventh consecutive year, allowing real-time online voting until polls closed.
Directors, officers, the independent auditor, and legal counsel were present virtually.
The meeting followed company bylaws and Delaware law, with notice and proxy materials distributed to stockholders.
Board and executive committee updates
Nine incumbent directors were nominated for re-election to serve until the 2027 annual meeting.
No stockholder nominations for director were received in advance.
Shareholder proposals
The agenda included the election of directors and ratification of the independent auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from ImmunityBio
- Q2 2026 revenue surged 92% year-over-year, but net loss widened on higher non-cash expenses.IBRX
Q2 2026 - ANKTIVA delivers durable cancer responses, drives global growth, and expands into new indications.IBRX
Jefferies Global Healthcare Conference 2026 - Q1 2026 revenue surged 168% to $44.2M, but net loss deepened to $632.8M on non-cash charges.IBRX
Q1 2026 - Director elections and auditor ratification headline the June 2026 virtual shareholder meeting.IBRX
Proxy filing - Record revenue growth, global approvals, and robust governance highlight this year's proxy.IBRX
Proxy filing - Global immunotherapy expansion accelerates with durable clinical results and new market launches.IBRX
The Citizens Life Sciences Conference 2026 - ANKTIVA drives global immunotherapy growth with strong efficacy, approvals, and financial momentum.IBRX
Investor presentation - 700% revenue growth to $113M, global expansion, and net loss narrowed to $351M.IBRX
Q4 2025 - Immunotherapy platform achieves FDA approval, durable remissions, and global expansion momentum.IBRX
Investor Day 2025